| In response to difficulties prescribing anti-tumour drugs after their inclusion in health insurance, and to issues arising from DRG [Diagnosis-Related Group] and disease-based payment policies that lead severely ill patients to undergo staged surgeries or be discharged and readmitted, will raise these concerns with regulators in coordination with the media. | Cancro
> Cancro: a maioria dos tipos | Parceria regulatória
> A trabalhar com organismos reguladores | 100 000 | National | Sometimes | 114998326269 |
| We submit surveys/proposals to CFDA [China Food and Drug Administration] and CDE [Center for Drug Evaluation]. | Respiratório
> Hipertensão pulmonar | Parceria regulatória
> A trabalhar com organismos reguladores | 10 000 | National | Regularly | 115007302730 |
| With respect to newly marketed medicinal products, in our capacity as the initiating body of a patient assistance programme, we gather patient perspectives and, where a therapy demonstrably meets patients' clinical needs and no clinically equivalent alternative is available in China, we advocate for its market authorisation in the country — as we have done for medicines such as secukinumab [biologic medication used to treat autoimmune conditions like plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis] and Nefecon [corticosteroid budesonide used to treat primary Immunoglobulin A nephropathy]. | Saúde geral
> Saúde pública | Parceria regulatória
> Contribuir para submissões de Autorização de Introdução no Mercado | 100 000 | National | Sometimes | 115023378250 |
| I have received an invitation from the CDE [药品审评中心 – Center for Drug Evaluation] to participate in a closed-door meeting. | Cancro
> Cancro: sangue | Parceria regulatória
> Participar/facilitar reuniões com decisores políticos/reguladores | 100 000 | National | Rarely | 115007439380 |
| Roundtable discussions are primarily convened by invitation from the NMPA [National Medical Products Administration]. | Cancro
> Cancro: sangue | Parceria regulatória
> Participar/facilitar reuniões com decisores políticos/reguladores | 100 000 | National | Rarely | 115008256034 |
| Communicating and raising concerns with the NHSA [国家医疗保障局 – National Healthcare Security Administration/China]. | Raro
> Doença de Fabry | Parceria regulatória
> Participar/facilitar reuniões com decisores políticos/reguladores | 1000 | National | Regularly | 115013642356 |
| We use questionnaires to gather insights into the patient population and share the resulting survey data at meetings with policymakers. | Cancro
> Cancro: a maioria dos tipos | Parceria regulatória
> Participar/facilitar reuniões com decisores políticos/reguladores | 100 000 | National | Sometimes | 115033327817 |
| Participating in policy consultations and attending regulatory authority-led seminars that incorporate patient perspectives. | Raro
> Doenças raras: a maioria dos tipos | Parceria regulatória
> Participar/facilitar reuniões com decisores políticos/reguladores | 5000 | National | Rarely | 115063429838 |
| Submitting advocacy letters to regulatory authorities. | Raro
> Doenças raras: a maioria dos tipos | Impacto nas políticas e legislação
> Influenciar a política e legislação de saúde | 1000 | National | Regularly | 115029711188 |
| Policy advocacy and healthcare access support constitute the core areas of business. | Fígado
> Hepatite | Impacto nas políticas e legislação
> Influenciar a política e legislação de saúde | 100 000 | National | Regularly | 115050575369 |
| Proposals submitted to the Lianghui [两会 – the annual plenary sessions of China's National People's Congress and the Chinese People's Political Consultative Conference]. | Saúde geral
> Saúde pública | Impacto nas políticas e legislação
> Participar em audiências públicas e consultas | 100 000 | National | Regularly | 115023383007 |
| Participating in policy consultations and attending regulatory authority-led seminars that incorporate patient perspectives. | Raro
> Doenças raras: a maioria dos tipos | Impacto nas políticas e legislação
> Participar em audiências públicas e consultas | 5000 | National | Rarely | 115063429838 |
| We conduct research — covering areas such as pricing and related matters — and relay the findings to the relevant regulatory authorities. | Cancro
> Cancro: a maioria dos tipos | Defesa de preços e acessibilidade financeira
> Defender preços justos para medicamentos | 100 000 | National | Sometimes | 115030437530 |
| Patient-facing media advocacy content relating to healthcare insurance coverage. | Cancro
> Cancro: a maioria dos tipos | Defesa de preços e acessibilidade financeira
> Defender preços justos para medicamentos | 100 000 | National | Sometimes | 115032740364 |
| We raise our voice on the issue of drug pricing. | Endócrino
> Diabetes: tipo 2 | Defesa de preços e acessibilidade financeira
> Defender preços justos para medicamentos | 10 000 | Regional | Rarely | 115051912364 |
| In our capacity as the initiating organization of a Patient Assistance Program (PAP) for newly approved medicines, we gather and represent patient perspectives. Where a genuine unmet clinical need exists and no clinically viable alternative is available in China, we advocate for the regulatory approval and market authorization of therapies such as secukinumab [biologic medication used to treat autoimmune conditions like plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis] and Nefecon [corticosteroid budesonide used to treat primary Immunoglobulin A nephropathy], while providing evidence on the financial burden borne by patients. | Saúde geral
> Saúde pública | Defesa de preços e acessibilidade financeira
> Abordar as barreiras de custo para pessoas de baixo rendimento e vulneráveis | 100 000 | National | Sometimes | 115023378250 |
| In response to difficulties prescribing anti-tumour drugs after their inclusion in the NRDL [ 国家医保药品目录 - China's National Reimbursement Drug List], and to issues arising from DRG [Diagnosis-Related Group] and disease-based payment policies that lead severely ill patients to undergo staged surgeries or be discharged and readmitted, we will raise these concerns with regulators in coordination with the media. | Cancro
> Cancro: a maioria dos tipos | Defesa de preços e acessibilidade financeira
> Monitorização e acompanhamento de preços de medicamentos/escassez de medicamentos | 100 000 | National | Sometimes | 114998326269 |
| We conduct research — covering areas such as pricing and related matters — and relay the findings to the relevant regulatory authorities. | Cancro
> Cancro: a maioria dos tipos | Defesa de preços e acessibilidade financeira
> Monitorização e acompanhamento de preços de medicamentos/escassez de medicamentos | 100 000 | National | Sometimes | 115030437530 |
| We advocate for the inclusion of medications within the national medical insurance formulary, as well as for greater ease of access to treatments. | Neurológico
> Esclerose múltipla | Defesa de preços e acessibilidade financeira
> Defender a inclusão do produto em listas de reembolso/formulários nacionais | 10 000 | National | Sometimes | 115000464773 |
| We advocate for the inclusion of medications within the national medical insurance formulary, as well as for greater ease of access to treatments. | Neurológico
> Esclerose múltipla | Defesa de preços e acessibilidade financeira
> Defender a inclusão do produto em listas de reembolso/formulários nacionais | 10 000 | National | Sometimes | 115000464773 |
| I will advocate on issues relating to pharmaceutical pricing and the inclusion of pharmaceutical products and medical devices in the national medical insurance (NMI) reimbursement market. | Endócrino
> Diabetes: tipo 2 | Defesa de preços e acessibilidade financeira
> Defender a inclusão do produto em listas de reembolso/formulários nacionais | 10 000 | Regional | Rarely | 115051912364 |
| Patient-facing media advocacy content relating to healthcare insurance coverage [in China]. | Cancro
> Cancro: a maioria dos tipos | Melhorar os caminhos de acesso
> Facilitar o acesso equitativo a medicamentos/cuidados de saúde | 100 000 | National | Sometimes | 115032740364 |
| For example, patient narratives can be disseminated through media channels to communicate patient needs around medicine accessibility. | Cancro
> Cancro: a maioria dos tipos | Melhorar os caminhos de acesso
> Facilitar o acesso equitativo a medicamentos/cuidados de saúde | 100 000 | National | Rarely | 115037193619 |
| For example, once a medicine is included in centralised procurement, it becomes unavailable for purchase outside of hospital settings. | Reumático
> Lúpus | Melhorar os caminhos de acesso
> Facilitar o acesso equitativo a medicamentos/cuidados de saúde | 100 000 | National | Sometimes | 115046738886 |
| Policy advocacy and healthcare access support constitute the core areas of business. | Fígado
> Hepatite | Melhorar os caminhos de acesso
> Facilitar o acesso equitativo a medicamentos/cuidados de saúde | 100 000 | National | Regularly | 115050575369 |
| For example, once a medicine is included in centralised procurement, it becomes unavailable for purchase outside of hospital settings. | Reumático
> Lúpus | Melhorar os caminhos de acesso
> Abordar disparidades no acesso e gestão | 100 000 | National | Sometimes | 115046738886 |
| Patient needs and concerns should be communicated to policy-making bodies such as the National Healthcare Security Administration [国家医疗保障局 – China's national authority responsible for healthcare security and reimbursement policy]. | Pele
> Condições de pele: a maioria dos tipos | Contribuição do doente baseada em evidências
> Utilize os insights dos pacientes para informar decisões | 100 000 | National | Sometimes | 115007238824 |
| With respect to newly marketed medicinal products, in our capacity as the initiating body of a patient assistance programme, we gather patient perspectives and, where a therapy demonstrably meets patients' clinical needs and no clinically equivalent alternative is available in China, we advocate for its market authorisation in the country — as we have done for medicines such as secukinumab [biologic medication used to treat autoimmune conditions like plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis] and Nefecon [corticosteroid budesonide used to treat primary Immunoglobulin A nephropathy]. | Saúde geral
> Saúde pública | Contribuição do doente baseada em evidências
> Utilize os insights dos pacientes para informar decisões | 100 000 | National | Sometimes | 115023378250 |
| We use questionnaires to gather insights into the patient population and share the resulting survey data at meetings with policymakers. | Cancro
> Cancro: a maioria dos tipos | Contribuição do doente baseada em evidências
> Utilize os insights dos pacientes para informar decisões | 100 000 | National | Sometimes | 115033327817 |
| For example, patient narratives can be disseminated through media channels to communicate patient needs around medicine accessibility. | Cancro
> Cancro: a maioria dos tipos | Contribuição do doente baseada em evidências
> Aproveite histórias de pacientes e narrativas de experiências vividas | 100 000 | National | Rarely | 115037193619 |
| We conduct research — covering areas such as pricing and related matters — and relay the findings to the relevant regulatory authorities. | Cancro
> Cancro: a maioria dos tipos | Contribuição do doente baseada em evidências
> Realizar inquéritos/pesquisas para gerar dados | 100 000 | National | Sometimes | 115030437530 |
| We use questionnaires to gather insights into the patient population and share the resulting survey data at meetings with policymakers. | Cancro
> Cancro: a maioria dos tipos | Contribuição do doente baseada em evidências
> Realizar inquéritos/pesquisas para gerar dados | 100 000 | National | Sometimes | 115033327817 |
interações
ações & defesa
8 menções
